Emilie Ludeman

Emilie Ludeman

Auto-generated profile, based on publicly available information

Emilie Ludeman

Health Sciences and Human Services Library, University of Maryland , Baltimore, Maryland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in Sleep Medicine Reviews
Verified
Journal Article
Closed access
JGJeanne M. Geiger-Brown
Jeanne M. Geiger-Brown
VRValerie E. Rogers
Valerie E. Rogers
WLWen Liu
Wen Liu
ELEmilie M. Ludeman
Emilie M. Ludeman
KDKatherine D. Downton
Katherine D. Downton
MDMontserrat Diaz-Abad
Montserrat Diaz-Abad

1 March 2017 in Journal of Professional Nursing
Verified
Journal Article
Closed access
VNVeronica P.S. Njie-Carr
Veronica P.S. Njie-Carr
ELEmilie Ludeman
Emilie Ludeman
MLMei Ching Lee
Mei Ching Lee
DDDzifa Dordunoo
Dzifa Dordunoo
NTNina M. Trocky
Nina M. Trocky
LJLouise S. Jenkins
Louise S. Jenkins

1 August 2016 in Child Abuse & Neglect
Verified
Journal Article
Closed access
WLWendy Lane
Wendy Lane
PSPaul Sacco
Paul Sacco
KDKatherine Downton
Katherine Downton
ELEmilie Ludeman
Emilie Ludeman
LLLauren Levy
Lauren Levy
JTJ. Kathleen Tracy
J. Kathleen Tracy

3 April 2015 in Medical Reference Services Quarterly
Verified
Journal Article
Closed access
ELEmilie Ludeman
Emilie Ludeman
KDKatherine Downton
Katherine Downton
ASAndrea Goldstein Shipper
Andrea Goldstein Shipper
YFYunting Fu
Yunting Fu
Systematic review searching is a standard job responsibility for many health sciences librarians. The strategies a library uses to market its expertise may affect the number of researchers requesting librarian assistance as well as how researchers perceive librarians as systematic review collaborators. This article describes how one health sciences library developed, launched, and promoted its systematic review service to researchers on campus.

1 April 2014 in Biologics: Targets and Therapy
Verified
Journal Article
Open access
MDMary Lynn Davis-Ajami
Mary Lynn Davis-Ajami
JWJun Wu
Jun Wu
KDKatherine Downton
Katherine Downton
ELEmilie Ludeman
Emilie Ludeman
VNVirginia Noxon
Virginia Noxon
Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility Mary Lynn Davis-Ajami,1 Jun Wu,2 Katherine Downton,3 Emilie Ludeman,3 Virginia Noxon4 1Organizational Systems and Adult Health, University of Maryland School of Nursing, Baltimore, MD, USA; 2South Carolina College of Pharmacy, University of South Carolina, Greenville, SC, USA; 3Health Sciences and Human Services Library, University of Maryland, Baltimore, MD, USA; 4Department of Clinical Pharmacy and Outcomes Science, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, USA Epoetin zeta was granted marketing authorization in October 2007 by the European Medicines Agency as a recombinant human erythropoietin erythropoiesis-stimulating agent to treat symptomatic anemia of renal origin in adult and pediatric patients on hemodialysis and adults on peritoneal dialysis, as well as for symptomatic renal anemia in adult patients with renal insufficiency not yet on dialysis. Currently, epoetin zeta can be administered either subcutaneously or intravenously to correct for hemoglobin concentrations ≤10 g/dL (6.2 mmol/L) or with dose adjustment to maintain hemoglobin levels at desired levels not in excess of 12 g/dL (7.5 mmol/L). This review article focuses on epoetin zeta indications in chronic kidney disease, its use in managing anemia of renal origin, and discusses its pharmacology and clinical utility. Keywords: biosimilar, chronic kidney disease, epoetin alfa, erythropoiesis, renal anemia, Retacrit®